Blog

The healthtech market is moving quickly and past its "wild west" phase. The initial flood of innovation is giving way to a more disciplined and mature market where the ability to prove a unique, valuable and sustainable advantage is paramount. In this next phase of HealthTech's growth and maturation, differentiation will be the single most important factor for success in 2026 and beyond.1. Market Saturation and Consolidation The healthtech landscape has seen a massive influx of companies, especially following the acceleration of digital health during the pandemic. However, the funding environment is now shifting from a "growth at all costs" mentality to a more disciplined one.Fewer, Bigger Bets: Experts predict a move towards larger, more focused investments, with average deal sizes rising for late-stage companies. The "Me-Too" Problem: With so many similar products and services on the market (e.g., telemedicine platforms, wellness apps), companies can no longer rely on a novel idea alone. They must stand out. This environment of market consolidation and investor scrutiny means that companies without a clear, defensible differentiator will struggle to survive, let alone thrive.2. Shifting Demands of Healthcare Buyers Healthcare providers and systems are no longer interested in a patchwork of unintegrated digital tools. They want solutions that:Solve a Specific Problem: Buyers are looking for solutions that address a genuine need, such as reducing hospital admissions or filling staffing gaps. Integrate Seamlessly: Solutions that can't easily plug into existing systems like Electronic Health Records (EHRs) are increasingly being sidelined. Demonstrate ROI: There's a growing demand for solutions that can show measurable outcomes and align with reimbursement streams. This shift means that healthtech companies must differentiate themselves by proving their value, not just by having cool technology.3. The Rise of "Infrastructure, Not Add-On" &nbsp;The most successful healthtech companies in the coming years will be those that provide fundamental infrastructure, not just a standalone product. This involves:Personalised and Predictive Care: Differentiation will come from moving beyond a "one-size-fits-all" approach to offering highly personalized and predictive care. This is being powered by technologies like AI, genomics, and advanced data analytics. AI-Driven Specialization: Instead of generic AI chatbots, the focus will be on specialized AI tools that augment clinicians' capabilities in specific medical domains, such as chronic condition management or diagnostics. Seamless Patient Journeys: Companies that can digitize and connect fragmented patient journeys—from virtual assessments to in-person consultations—will create a differentiated and valuable "digital health operating system." 4. Key Differentiation StrategiesTo achieve this differentiation, healthtech companies are focusing on several key areas:Technological Innovation: Developing cutting-edge technologies that address unmet needs, such as AI-powered diagnostic tools that detect diseases earlier.Targeted Audience Segmentation: Focusing on specific patient groups (e.g., a telemedicine platform for the elderly) or medical conditions (e.g., a platform for diabetes management).Data Security and Privacy: With the sensitive nature of health data, robust security and compliance with regulations like HIPAA will become a crucial differentiator and a "go/no-go" factor for enterprise sales.Clinical Validation: Companies that can provide rigorous clinical trials and evidence-based research to validate their solutions will build trust with both providers and patients.Partnerships and Collaborations: Teaming up with hospitals, pharmaceutical companies, or other ecosystem players to enhance credibility and market reach. In summary, the healthtech market is maturing. The initial wave of innovation has paved the way, and now the next phase is about separating the truly valuable solutions from the noise. In this new landscape, a company's ability to clearly articulate and prove its differentiation will be the defining factor for its success in 2026 and beyond.To discuss any of these trends and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Why differentiation will become the key phrase in HealthTech in 2026

The European healthtech landscape in 2026 is poised for a period of significant change, where companies will likely face a stark choice: be acquired or risk becoming obsolete. This dynamic is being shaped by several key trends.The Rise of Acquisitions and Consolidation The healthtech market in Europe is experiencing robust M&amp;A activity, with predictions for continued growth through 2026. This trend is driven by several factors:Strategic Imperative: Large corporations, both within and outside of healthcare, are looking to optimize their portfolios and invest in high-growth, technologically advanced areas. This leads them to acquire smaller, innovative companies to quickly gain access to new technologies, talent, and market share.Technological Advancements: The rapid evolution of technologies like AI, digital health, and remote patient monitoring is a primary catalyst for M&amp;A. Companies with expertise in these areas, particularly in AI-powered diagnostics, telemedicine, and digital therapeutics, are prime targets. Tech giants like Microsoft are also entering the space by acquiring healthtech founders and startups to bolster their AI divisions.Favourable Economic and Regulatory Conditions: Falling interest rates are making acquisitions more financially attractive for both strategic and financial buyers. Additionally, a more deal-friendly stance from regulatory bodies like the UK's Competition and Markets Authority is encouraging M&amp;A activity. The European Single Market also facilitates cross-border deals, allowing companies to scale operations and access larger markets.Private Equity and Venture Capital: PE and VC firms are key players, driving consolidation through platform acquisitions and "bolt-on" deals. The maturing healthtech market is seeing larger firms acquire niche players to create more comprehensive offerings. The Threat of ObsolescenceFor many healthtech companies, particularly startups, the alternative to acquisition is a significant risk of obsolescence. This is due to a combination of market pressures and internal challenges:Intense Competition: The market is becoming increasingly crowded, with a proliferation of startups and solutions. Companies that fail to differentiate themselves or achieve significant scale are at risk of being outpaced by more established players or better-funded competitors. Underestimating Regulatory Hurdles: The European regulatory landscape, while evolving, remains complex. Startups often underestimate the time and resources required for clinical validation, regulatory readiness, and compliance with data privacy laws like GDPR. This can create a significant bottleneck and a major barrier to market entry and scaling.Lack of Integration and Interoperability: A major challenge for health systems is integrating innovative point solutions into their existing, often legacy, IT architecture. Companies that offer stand-alone solutions that don't seamlessly integrate with Electronic Health Records (EHRs) and other systems are less attractive to healthcare providers and more likely to be overlooked.Funding and Capital: While early-stage funding remains resilient, investors are becoming more selective and data-driven. They are seeking startups with clear clinical validation, strong go-to-market strategies, and solid business models. Companies that struggle to demonstrate these qualities may find it difficult to secure the necessary capital to survive and scale.Key Areas of Focus for 2026To thrive in this environment, healthtech companies will need to focus on several key areas:AI and Digital Health: The integration of AI, particularly generative AI, is no longer a novelty but a non-negotiable part of the industry. Solutions in areas like AI-powered diagnostics, telemedicine, and remote patient monitoring will continue to be in high demand.Data and Interoperability: With the European Health Data Space (EHDS) and the AI Act moving fast, companies must prioritize robust data strategies and solutions that ensure interoperability and compliance.Specialisation and Niche Expertise: While the market is consolidating, there is still a strong appetite for niche players with expertise in high-growth verticals like mental health tech, femtech, and preventive care.Patient-Centricity: The focus is shifting towards patient-centric and outcome-driven business models. Technologies that improve real-world health outcomes and provide a seamless, convenient experience for patients will be most successful.To discuss any of these trends and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

HealthTech Europe 2026: Acquisition or Obsolescence

Shareholder agreements for healthtech startups often include preferred shares, which have rights that are superior to common shares. Within preferred shares, the most critical distinction for founders to understand is between participatingand non-participating preferences, as this directly impacts how much money investors receive during a liquidity event (like an acquisition or IPO) and consequently, how much is left for the founders and common shareholders.Non-Participating Preferred Stock 🤝This is the most common and founder-friendly type of preferred stock.How it Works: When a company is sold, non-participating preferred shareholders have a choice:Get their money back: They can take their initial investment back, plus any accrued dividends. Convert to common stock: They can convert their preferred shares into common shares and get their proportional share of the sale proceeds, just like everyone else. Payout Logic: They will choose whichever option gives them a higher return. For example, if an investor put in $10 million for 20% of the company and the company sells for $100 million, they will get $20 million by converting to common stock (20% of $100 million), not just their initial $10 million back. The Founder's Takeaway: This model means investors get a return or a proportional share of the equity, but not both. This leaves more value for founders and common shareholders, especially in a high-value exit. Participating Preferred Stock 💰This type of preferred stock is less common for early-stage companies and is generally more investor-friendly.How it Works: Participating preferred shareholders get their initial investment back first, and then they get to participate in the remaining sale proceeds along with the common shareholders, based on their ownership percentage.Payout Logic: The investor's payout is a two-step process:Liquidation Preference: The investor gets their initial investment back off the top. Participation: After the initial investment is returned, the remaining money is distributed as if the preferred shares had converted to common stock. The investor gets their proportional share of this remaining pot.Example: An investor puts in $10 million for 20% of the company, and the company sells for $100 million.Liquidation Preference: The investor gets their $10 million back. This leaves $90 million for distribution.Participation: The investor then gets their 20% of the remaining $90 million, which is $18 million.Total Payout: The investor's total payout is $10 million (liquidation preference) + $18 million (participation) = $28 million.The Founder's Takeaway: This structure is less favorable for founders because investors double-dip, taking both their money back first and a proportional share of the remaining value. It significantly reduces the size of the payout for common shareholders, particularly in moderate-to-low-value exits. &nbsp; Key Differences and Founder's Action PlanNegotiate for Non-Participating: Always push for non-participating preferred stock. It is the industry standard for most early-stage venture capital. Look for a Cap: If an investor insists on a participating preference, try to negotiate a participation cap. A cap limits the total amount the investor can receive. For example, a "2x cap" means the investor's total return from the deal (liquidation preference + participation) cannot exceed twice their initial investment. This limits the investor's double-dipping and protects the founder's upside.

Understanding Participating v Non Participating Preferences: A Cheat Sheet for HealthTech Founders

Healthcare technology M&amp;A deals in Europe are facing a number of challenges that are causing them to fail or become more difficult to complete in the current market. While the sector remains attractive due to long-term trends like an aging population and the need for efficiency, several factors are creating a more cautious and complex environment for dealmakers.&nbsp;Here are the primary reasons why European healthcare technology M&amp;A deals are going wrong:1. Macroeconomic and Financial HeadwindsThe broader economic climate is a significant factor in deal failures.&nbsp;Higher Cost of Capital: Increased interest rates have made it more expensive for private equity firms and corporations to finance acquisitions, especially leveraged buyouts. This directly impacts deal valuations and can make some transactions financially unfeasible.Valuation Gap: A major issue is the mismatch between what sellers expect and what buyers are willing to pay.Sellers often have valuation expectations based on the high-flying market of 2021-2022. However, buyers are now more disciplined, prioritizing profitability and sustainable revenue models over rapid growth. This discrepancy often causes deals to collapse during due diligence.&nbsp; &nbsp; Shift to Profitability: Investors are less tolerant of companies that prioritize aggressive growth at the expense of profitability. Healthtech companies that scaled rapidly during the pandemic but lack a clear path to profitability are seen as less attractive targets, making it difficult for them to secure an exit.2. Regulatory and Data Privacy ComplexityThe highly regulated nature of healthcare, combined with a fragmented European landscape, creates significant hurdles.Data Privacy (GDPR): The General Data Protection Regulation (GDPR) is a major concern. Due diligence must be extremely thorough to ensure a target company is fully compliant with all data privacy regulations. Any significant gaps can be a deal-breaker, as breaches can lead to severe fines and reputational damage.Varying National Regulations: Unlike the more unified U.S. market, Europe is a patchwork of different countries with their own healthcare systems, reimbursement frameworks, and regulations. A healthtech product that is successful in Germany may not be compliant or reimbursable in France, adding complexity and risk to cross-border deals. Antitrust Scrutiny: Regulatory bodies are increasingly scrutinizing M&amp;A deals to prevent consolidation that could reduce competition and harm consumers.&nbsp;3. Integration and Operational ChallengesEven after a deal closes, the post-merger integration phase is fraught with risks.IT and System Interoperability: Integrating the complex IT systems of two healthtech companies, especially their electronic health records (EHRs) or billing software, is a massive technical challenge. Achieving seamless data flow and interoperability can be costly and time-consuming, diminishing the strategic value of the acquisition.Cultural and People Integration: Merging two companies with different cultures and operational styles can lead to internal friction and key personnel leaving. This is particularly relevant in the high-tech sector where talent is a critical asset.Diligence on Technology and AI: The rise of AI adds a new layer of complexity to due diligence. Buyers must carefully evaluate a target company's AI technology, ensuring it is compliant with emerging regulations and that its use is defensible and scalable.In summary, the European healthcare technology M&amp;A market is maturing, with a higher bar for success. Deals are no longer driven by a "growth at all costs" mentality. Instead, successful transactions require meticulous due diligence to navigate a fragmented regulatory landscape, a clear path to profitability, and a realistic valuation that accounts for the current economic environment.

Why do European Healthcare Technology M&A deals go wrong in today's market?

Unique and proprietary healthcare biomarker datasets are crucial for developing advanced AI and ML models that can discover new biomarkers, enhance diagnostics and create personalised treatment plans. These datasets provide a competitive advantage by offering specific, high-quality data that public datasets often lack, allowing for more precise and effective model training.Why Proprietary Datasets are a Game Changer While public datasets like those from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and The Cancer Genome Atlas (TCGA) are valuable for foundational research, proprietary datasets offer a distinct advantage. These unique data sets are often gathered through specific clinical trials, collaborations, or advanced lab testing, providing a more detailed and controlled view of a particular disease or patient population.Key characteristics of these valuable datasets include:Multimodal data: Integrating various data types like genomics (e.g., DNA, RNA), proteomics (e.g., proteins, peptides), metabolomics (e.g., metabolites), and medical imaging (e.g., MRI, CT scans) provides a holistic view of a patient's health.Longitudinal data: Datasets that track patients over extended periods offer insights into disease progression and treatment response, which is crucial for developing prognostic and predictive biomarkers.High-quality and curated data: Unlike raw data, which can be messy and inconsistent, proprietary datasets are often meticulously cleaned, harmonized, and annotated. This "AI-ready" data is essential for training robust and accurate models.Unique patient populations: These datasets can focus on rare diseases, specific demographics, or patients with particular genetic profiles, enabling the development of highly specialized AI models.Applications in Healthcare AIUsing unique biomarker datasets, AI and ML algorithms can unlock new possibilities in several healthcare domains.Biomarker Discovery: AI models can analyze complex, high-dimensional data to identify novel biomarkers that might be undetectable to human researchers. For example, machine learning algorithms can analyze patterns in wearable device data to detect early signs of cardiovascular problems.Personalised Medicine: By integrating genomic, clinical, and environmental data, AI can create a comprehensive patient profile. This allows for the selection of the most effective therapy and dosage for an individual, minimizing the "trial-and-error" approach to treatment.Diagnostics and Prognostics: AI-powered models trained on specific biomarker data can improve the accuracy of disease diagnosis and predict a patient's likely outcome. This helps clinicians make more informed decisions and plan timely interventions.Drug Discovery and Clinical Trials: AI can use biomarker data to simulate drug interactions, identify suitable patient cohorts for clinical trials, and predict the potential success of new drug candidates. This streamlines the drug development process, making it faster and more cost-effective.Email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a> to discuss further.

Healthcare biomarker datasets enhancing AI models and ML algorithms

The intersection of private equity continuation funds and the healthcare technology sector is a particularly dynamic trend in 2025. This area is seeing significant activity driven by both the unique characteristics of health tech and the broader market forces shaping the private equity landscape.Here are the key trends for private equity continuation funds in healthcare technology in 2025:1. A Solution for Extended Value Creation in Complex MarketsHealthcare technology assets often require longer investment horizons than typical private equity investments. This is due to the time it takes to navigate:Regulatory Hurdles: Gaining approvals from bodies like the FDA and ensuring compliance with regulations such as HIPAA is a lengthy and complex process.Reimbursement Models: Establishing and scaling a profitable business model often depends on securing favorable reimbursement from private insurers and government programs (e.g., Medicare and Medicaid), which can take several years.Implementation and Adoption Cycles: Selling to large hospital systems or healthcare providers involves long sales cycles and slow integration processes.Continuation funds are a perfect fit for this scenario. They allow a GP to "hold and grow" a high-performing health tech company beyond the typical 10-year fund life. This gives the GP and the management team the necessary time to mature the company, secure regulatory approvals, and achieve a critical mass of adoption, ultimately positioning it for a more lucrative exit.2. Focus on "Crown Jewel" Digital Health AssetsPrivate equity firms are not using continuation funds to exit underperforming health tech companies. Instead, the trend is to move "crown jewel" assets into a new vehicle. These are companies with:Strong, recurring revenue models: Particularly those with a Software-as-a-Service (SaaS) component.Proven clinical efficacy: The technology has demonstrated a positive impact on patient outcomes or operational efficiency.Scalable platforms: The technology can be easily expanded to new markets or customer segments.Substantial growth potential: The company is well-positioned to capitalize on mega-trends like aging populations, telehealth, and value-based care.The continuation fund provides a fresh capital injection to fund strategic initiatives, such as tuck-in acquisitions to expand a company's offerings or to accelerate international expansion, further enhancing its value.3. AI and Data Analytics as Key DriversThe use of artificial intelligence (AI) and data analytics is revolutionizing healthcare, and this is a significant driver of continuation fund activity. PE firms are using these vehicles to back health tech companies that are:Developing AI-powered solutions: These could be for drug discovery, diagnostic tools, or administrative workflow automation.Leveraging large datasets: Companies that can effectively use patient data to improve care delivery or personalize treatments are highly sought after.Paving the way for new reimbursement pathways: Proposed legislation, such as the "Health Tech Investment Act," which aims to create a stable Medicare payment pathway for algorithm-based services, is de-risking investment in this space and making these companies more attractive for long-term holds. 4. Increased Scrutiny and Evolving GovernanceAs private equity's role in healthcare becomes more prominent, so does the scrutiny from regulators and the public. This is a crucial factor shaping continuation fund deals in 2025.State-level oversight: Several states are passing or considering legislation to regulate PE deals in healthcare, particularly those involving a "Management Services Organization" (MSO) model. This adds a layer of complexity and risk that needs to be carefully managed in a continuation fund's structure.Antitrust and fraud enforcement: Federal agencies are ramping up their enforcement actions against anti-competitive practices and healthcare fraud. GPs must ensure their health tech portfolio companies have robust compliance programs to mitigate these risks.Transparency and fairness: The established trend of using independent third-party valuations and advisory committees to ensure fair pricing and a smooth process for LPs cashing out is even more critical in the sensitive healthcare sector.In summary, continuation funds in healthcare technology are a powerful tool for private equity in 2025. They provide a mechanism to maximize the value of high-potential assets in a sector characterized by long development cycles and complex regulatory landscapes, while also addressing the growing need for liquidity and distributions to LPs. The focus remains on quality assets, particularly those leveraging AI and data, but the transactions are increasingly structured with heightened attention to governance and regulatory compliance.

Nelson Advisors

Blog

Why differentiation will become the key phrase in HealthT...

HealthTech Europe 2026: Acquisition or Obsolescence

Understanding Participating v Non Participating Preferenc...

Why do European Healthcare Technology M&A deals go wrong ...

Healthcare biomarker datasets enhancing AI models and ML ...

Private Equity continuation funds trend in Healthcare Tec...